- Home
- PRAX vs MAX Comparison
PRAX vs MAX Comparison
Compare PRAX & MAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- MAX
- Stock Information
- Founded
- PRAX 2015
- MAX 2014
- Country
- PRAX United States
- MAX United States
- Employees
- PRAX N/A
- MAX N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- MAX Industrial Machinery/Components
- Sector
- PRAX Health Care
- MAX Industrials
- Exchange
- PRAX Nasdaq
- MAX Nasdaq
- Market Cap
- PRAX 599.7M
- MAX 582.4M
- IPO Year
- PRAX 2020
- MAX 2020
- Fundamental
- Price
- PRAX $38.55
- MAX $10.19
- Analyst Decision
- PRAX Strong Buy
- MAX Buy
- Analyst Count
- PRAX 10
- MAX 7
- Target Price
- PRAX $116.50
- MAX $17.21
- AVG Volume (30 Days)
- PRAX 320.6K
- MAX 463.2K
- Earning Date
- PRAX 05-02-2025
- MAX 04-30-2025
- Dividend Yield
- PRAX N/A
- MAX N/A
- EPS Growth
- PRAX N/A
- MAX N/A
- EPS
- PRAX N/A
- MAX 0.28
- Revenue
- PRAX $8,122,000.00
- MAX $1,002,364,000.00
- Revenue This Year
- PRAX N/A
- MAX $23.97
- Revenue Next Year
- PRAX N/A
- MAX $9.79
- P/E Ratio
- PRAX N/A
- MAX $36.80
- Revenue Growth
- PRAX 270.02
- MAX 148.62
- 52 Week Low
- PRAX $26.70
- MAX $7.33
- 52 Week High
- PRAX $91.83
- MAX $20.91
- Technical
- Relative Strength Index (RSI)
- PRAX 53.72
- MAX 56.36
- Support Level
- PRAX $35.21
- MAX $9.79
- Resistance Level
- PRAX $38.90
- MAX $10.60
- Average True Range (ATR)
- PRAX 2.09
- MAX 0.31
- MACD
- PRAX 0.07
- MAX -0.03
- Stochastic Oscillator
- PRAX 69.58
- MAX 41.98
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.